STAMPEDE otherwise follows a line of randomized trials (e.g., MAST, TAXOMET, IMPROVE) that have failed to prove cancer progression or survival benefits to metformin across disease stages. Gillessen's ...

Health groups led by the American Academy of Pediatrics filed a lawsuit against HHS Secretary Robert F. Kennedy Jr. on Monday ...

Lindsey Hudson began to suspect her sleep habits weren’t the norm during her freshman year at Southern Nazarene University in Oklahoma. A competitive high school cheerleader, teenage Lindsey—busy with ...

It is often said that every cloud has a silver lining. And where agriculture is concerned, the light at the end of the tunnel ...

Clashes erupted on Sunday in Sweida, in southern Syria, before a tit-for-tat exchange between armed Bedouin and Druze ...

Myriad Genetics’ first quarter results were met with a significant negative market reaction, reflecting investor concerns over a combination of volume softness in key product lines and a reset ...

Monash University scientists have uncovered how invasive plants like white clover rapidly adapt to new environments, ...

Read about Myriad Genetics Inc (MYGN:XNAS) stock and today's latest news and financial updates.

Teeth may seem like static fixtures, but a new collaboration between engineers and clinicians is proving just how dynamic, ...

Our Top 5 Analyst Questions Myriad Genetics’s Q1 Earnings Call ・ Doug Schenkel (Wolfe Research) pressed CEO Sam Raha on how long it would take to simplify Myriad’s business and clarify key ...

A new study has revealed compelling evidence that brain criticality—a dynamic balance between neural excitation and inhibition—has a strong genetic foundation and is associated with cognitive ...

Review the current Myriad Genetics Inc (MYGN:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if MYGN is the best investment for you.